MedPath

ISARNA Therapeutics GmbH

ISARNA Therapeutics GmbH logo
🇩🇪Germany
Ownership
Holding
Established
1998-01-01
Employees
1
Market Cap
-
Website
http://www.isarna-therapeutics.com

Clinical Trials

5

Active:1
Completed:3

Trial Phases

3 Phases

Phase 1:3
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
1 (20.0%)
Phase 3
1 (20.0%)

Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy

Phase 1
Completed
Conditions
Primary Open Angle Glaucoma
Interventions
Drug: TGF-β2 antisense oligonucleotide
Procedure: Trabeculectomy
First Posted Date
2015-04-02
Last Posted Date
2018-02-28
Lead Sponsor
Isarna Therapeutics GmbH
Target Recruit Count
13
Registration Number
NCT02406833
Locations
🇩🇪

University Hospital Magdeburg, Ophthalmology, Magdeburg, Germany

🇩🇪

Department of Ophthalmology, Johannes-Gutenberg University Mainz, Mainz, Germany

🇩🇪

University of Tuebingen, Center of Ophthalmology, Tuebingen, Germany

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Phase 1
Completed
Conditions
Melanoma
Colorectal Neoplasms
Pancreatic Neoplasms
Interventions
First Posted Date
2009-02-13
Last Posted Date
2019-02-15
Lead Sponsor
Isarna Therapeutics GmbH
Target Recruit Count
62
Registration Number
NCT00844064
Locations
🇩🇪

Universitätsmedizin Berlin Charité, Berlin, Germany

🇩🇪

Universitätsklinik und Poliklinik für Innere Medizin I, Halle (Saale), Germany

🇩🇪

Hautklinik der Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany

and more 7 locations

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Phase 3
Terminated
Conditions
Anaplastic Astrocytoma
Glioblastoma
Interventions
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System
First Posted Date
2008-09-29
Last Posted Date
2014-11-14
Lead Sponsor
Isarna Therapeutics GmbH
Target Recruit Count
27
Registration Number
NCT00761280
Locations
🇺🇸

NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States

🇺🇸

Winthrop University Hospital, Mineola, New York, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

and more 64 locations

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2
Completed
Conditions
Glioblastoma
Anaplastic Astrocytoma
Interventions
Device: Drug delivery system for administration of AP 12009
Procedure: Placement of Drug Delivery System
First Posted Date
2007-02-06
Last Posted Date
2013-12-03
Lead Sponsor
Isarna Therapeutics GmbH
Target Recruit Count
141
Registration Number
NCT00431561
Locations
🇦🇹

Universitätsklinik Innsbruck; Abteilung für Neurochirurgie, Innsbruck, Austria

🇦🇹

Landes-Nervenklinik Wagner-Jauregg, Linz, Austria

🇦🇹

Kaiser Franz Josef Spital, Abteilung für Neurologie, Wien, Austria

and more 33 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.